alexa The basic biology of HER2.
Oncology

Oncology

Journal of Cancer Science & Therapy

Author(s): Rubin I, Yarden Y

Abstract Share this page

Abstract Human epidermal growth factor receptors (HER/erbB) constitute a family of four cell surface receptors involved in transmission of signals controlling normal cell growth and differentiation. A range of growth factors serve as ligands, but none is specific for the HER2 receptor. HER receptors exist as both monomers and dimers, either homo- or heterodimers. Ligand binding to HERI, HER3 or HER4 induces rapid receptor dimerization, with a marked preference for HER2 as a dimer partner. Moreover, HER2-containing heterodimers generate intracellular signals that are significantly stronger than signals emanating from other HER combinations. In normal cells, few HER2 molecules exist at the cell surface, so few heterodimers are formed and growth signals are relatively weak and controllable. When HER2 is overexpressed multiple HER2 heterodimers are formed and cell signaling is stronger, resulting in enhanced responsiveness to growth factors and malignant growth. This explains why HER2 overexpression is an indicator of poor prognosis in breast tumors and may be predictive of response to treatment. HER2 is a highly specific and promising target for new breast cancer treatments. The recombinant human anti-HER2 monoclonal antibody (rhuMAb-HER2, trastuzumab, Herceptin) induces rapid removal of HER2 from the cell surface, thereby reducing its availability to heterodimers and reducing oncogenicity.
This article was published in Ann Oncol and referenced in Journal of Cancer Science & Therapy

Relevant Expert PPTs

Relevant Speaker PPTs

  • Hedef Dhafir El-Yassin
    The Immune Response of Prolactin and the Induction of Tumor Necrosis Factor (TNF) in Iraqi Patients Infected with Hepatitis C Virus
    PPT Version | PDF Version
  • Moshe Giladi
    Tumor Treating Fields (TTFields) induced cancer cell death may be immunogenic resulting in enhanced antitumor efficacy when combined with immune-modulating therapy
    PPT Version | PDF Version
  • Ping Yang
    Chronic obstructive pulmonary disease (COPD) complicating early-stage lung cancer (LC)
    PDF Version
  • Al-Said A. Haffor
    Effects of O2 Breathing on the Diaphragm's and the Lungs' Ultra-structural Pathological Changes in Relation to Free Radicals Accumulation
    PDF Version
  • M Shahnawaz Khan
    Graphene Oxide @ Gold Nanorods Conjugate for Controlled Release of Doxorubicin in tumor
    PPT Version | PDF Version
  • Li-Chun Tsou
    Drug delivery device strategy for patient centric therapies
    PDF Version
  • Omar E Franco
    Heterogeneous Tumor Stroma and Prostate Carcinogenesis
    PPT Version | PDF Version
  • Jan Scicinski
    RRx-001, a novel ROS-mediated epigenetic modulator: ‘Episensitization’ to previously failed therapies
    PPT Version | PDF Version
  • Yen-Chein Lai
    Molecular pathogenesis in granulosa cell tumor is not only due to somatic FOXL2 mutation
    PPT Version | PDF Version
  • Babak Behnam
    SLUG and SOX9 Cooperatively Regulate Tumor Initiating Niche Factors in Breast Cancer
    PPT Version | PDF Version
  • Yosef Yarden
    Classically, the 3’untranslated region (3’UTR) is that region in eukaryotic protein-coding genes from the translation termination codon to the polyA signal. It is transcribed as an integral part of the mRNA encoded by the gene. However, there exists another kind of RNA, which consists of the 3’UTR alone, without all other elements in mRNA such as 5’UTR and coding region. The importance of independent 3’UTR RNA (referred as I3’UTR) was prompted by results of artificially introducing such RNA species into malignant mammalian cells. Since 1991, we found that the middle part of the 3’UTR of the human nuclear factor for interleukin-6 (NF-IL6) or C/EBP gene exerted tumor suppression effect in vivo. Our subsequent studies showed that transfection of C/EBP 3’UTR led to down-regulation of several genes favorable for malignancy and to up-regulation of some genes favorable for phenotypic reversion. Also, it was shown that the sequences near the termini of the C/EBP 3’UTR were important for its tumor suppression activity. Then, the C/EBP 3’UTR was found to directly inhibit the phosphorylation activity of protein kinase CPKC in SMMC-7721, a hepatocarcinoma cell line. Recently, an AU-rich region in the C/EBP 3’UTR was found also to be responsible for its tumor suppression. Recently we have also found evidence that the independent C/EBP 3’UTR RNA is actually exists in human tissues, such as fetal liver and heart, pregnant uterus, senescent fibroblasts etc. Through 1990’s to 2000’s, world scientists found several 3’UTR RNAs that functioned as artificial independent RNAs in cancer cells and resulted in tumor suppression. Interestingly, majority of genes for these RNAs have promoter-like structures in their 3’UTR regions, although the existence of their transcribed products as independent 3’UTR RNAs is still to be confirmed. Our studies indicate that the independent 3’UTR RNA is a novel non-coding RNA species whose function should be the regulation not of the expression of their original mRNA, but of some essential life activities of the cell as a whole.
    PPT Version | PDF Version
  • Fan-Gang Tseng
    Fan-Gang-Tseng-National-Tsing-Hua-University-Taiwan-Nano-Micro-fluidic-systems-for-circulating-Tumor-Cells-(CTCs)-rapid-detection-and-diagnosis
    PPT Version | PDF Version
  • Myron R Szewczuk
    Therapeutic targeting neuraminidase-1 in multi-stage of tumorigenesis
    PPT Version | PDF Version
  • Hawa ZE Jaafar
    Involvement of elicitated Labisia pumila Benth. biofluids in the alleviation of chemotoxicity effect and antitumor activity
    PPT Version | PDF Version
  • Lourdes Cortes Dericks
    Cancer Stem Cell Markers in Lung Cancer: Proofs of Concept and Some Reservations
    PPT Version | PDF Version

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords